Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms. Researchers reported their findings in a poster presented at Psych Congress.
News
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. The drug, formerly known as KarXT, is the first new pharmacological treatment approved for schizophrenia in over 30 years.
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient Reported Outcomes.
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the US Food and Drug Administration (FDA), providing an alternate medication option for adults with tardive dyskinesia (TD) and chorea associated with Huntington disease.
Navigating treatment decisions for tardive dyskinesia involves more than just relying on the AIMS scale.